HomeCompareSDAD vs ABBV

SDAD vs ABBV: Dividend Comparison 2026

SDAD yields 2116.40% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SDAD wins by $16850188635.97M in total portfolio value
10 years
SDAD
SDAD
● Live price
2116.40%
Share price
$0.09
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$16850188636.07M
Annual income
$15,417,192,906,367,192.00
Full SDAD calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — SDAD vs ABBV

📍 SDAD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSDADABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SDAD + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SDAD pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SDAD
Annual income on $10K today (after 15% tax)
$179,894.18/yr
After 10yr DRIP, annual income (after tax)
$13,104,613,970,412,112.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, SDAD beats the other by $13,104,613,970,391,056.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SDAD + ABBV for your $10,000?

SDAD: 50%ABBV: 50%
100% ABBV50/50100% SDAD
Portfolio after 10yr
$8425094318.09M
Annual income
$7,708,596,453,195,982.00/yr
Blended yield
91.50%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

SDAD
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SDAD buys
0
ABBV buys
0
No recent congressional trades found for SDAD or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSDADABBV
Forward yield2116.40%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$16850188636.07M$102.3K
Annual income after 10y$15,417,192,906,367,192.00$24,771.77
Total dividends collected$16748912801.47M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SDAD vs ABBV ($10,000, DRIP)

YearSDAD PortfolioSDAD Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$222,340$211,640.21$11,550$430.00+$210.8KSDAD
2$4,635,673$4,397,769.11$13,472$627.96+$4.62MSDAD
3$90,652,793$85,692,623.21$15,906$926.08+$90.64MSDAD
4$1,663,129,343$1,566,130,853.69$19,071$1,382.55+$1663.11MSDAD
5$28,632,319,033$26,852,770,636.14$23,302$2,095.81+$28632.30MSDAD
6$462,688,385,745$432,051,804,380.31$29,150$3,237.93+$462688.36MSDAD
7$7,020,130,708,021$6,525,054,135,273.67$37,536$5,121.41+$7020130.67MSDAD
8$100,036,081,369,040$92,524,541,511,456.90$50,079$8,338.38+$100036081.32MSDAD
9$1,339,248,345,515,456$1,232,209,738,450,583.50$69,753$14,065.80+$1339248345.45MSDAD
10$16,850,188,636,068,730$15,417,192,906,367,192.00$102,337$24,771.77+$16850188635.97MSDAD

SDAD vs ABBV: Complete Analysis 2026

SDADStock

SH Resources & Development Corp. operates in the specialty finance industry. The company is based in Beverly Hills, California.

Full SDAD Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this SDAD vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SDAD vs SCHDSDAD vs JEPISDAD vs OSDAD vs KOSDAD vs MAINSDAD vs JNJSDAD vs MRKSDAD vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.